Abstract: Background: Asymptomatic E. coli 212 (ASB 212) has shown promise in dogs with recurrent UTI (rUTI)
Hypothesis: Administration of ASB 212 is noninferior to antimicrobial therapy for
Animals: Client-owned dogs with rUTI
Methods: Multicenter randomized noninferiority trial. Dogs were randomized to Group 1 (amoxicillin-clavulanic acid; 13.75-19mg/kg PO q12h for 7d) or Group 2 (intravesical administration of ASB 212; repeated if necessary). Owners completed a questionnaire regarding their dogs’ signs; data were analyzed using the Farrington-Manning test.
Results : Nine dogs were enrolled in Group 1 and 11 in Group 2. The median (range) clinical scores at day 0, 7 and 14 for Group 1 was 8 (3-17), 3 (0-6) and 2 (1-7), respectively. Group 2 scores were 8 (3-14), 4 (1-15) and 3 (1-15), respectively. After day 7, two Group 2 dogs were failures due to early withdrawal; 1 was lost to follow up. Five (55%) Group 1 dogs and 8 (72%) Group 2 dogs had > 65% reduction in their clinical score on day 7 compared to baseline. For day 7, Group 2 was not inferior to Group 1 according to the selected margin of noninferiority (20%; P= 0.04). Five of 9 dogs in Group 2 had E. coli cultured on day 7; bacterial strain typing is pending. No major adverse events were reported.
Conclusion and Clinical Importance: Clinical outcomes in some dogs treated with intravesical ASB 212 were positive. The biotherapeutic was easy to administer.